PCOS1
MCID: PLY105
MIFTS: 39

Polycystic Ovary Syndrome 1 (PCOS1)

Categories: Blood diseases, Endocrine diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Polycystic Ovary Syndrome 1

MalaCards integrated aliases for Polycystic Ovary Syndrome 1:

Name: Polycystic Ovary Syndrome 1 57 13
Stein-Leventhal Syndrome 57 73
Polycystic Ovary Syndrome 70
Hyperandrogenemia 57
Pco1; Pco 57
Pcos1 57
Pco1 57
Pcos 57
Pco 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant
probably heterogeneous


HPO:

31
polycystic ovary syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM® 57 184700
MedGen 41 C0032460
UMLS 70 C0032460

Summaries for Polycystic Ovary Syndrome 1

MalaCards based summary : Polycystic Ovary Syndrome 1, also known as stein-leventhal syndrome, is related to alopecia, androgenetic, 1 and cortisone reductase deficiency, and has symptoms including pelvic pain An important gene associated with Polycystic Ovary Syndrome 1 is PCOS1 (Polycystic Ovary Syndrome 1). The drugs Orlistat and Prednisolone acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and liver, and related phenotypes are obesity and enlarged polycystic ovaries

Wikipedia : 73 Polycystic ovary syndrome, or PCOS, is the most common endocrine disorder in women of reproductive age.... more...

More information from OMIM: 184700

Related Diseases for Polycystic Ovary Syndrome 1

Diseases in the Polycystic Ovary Syndrome family:

Polycystic Ovary Syndrome 1

Diseases related to Polycystic Ovary Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 11.1
2 cortisone reductase deficiency 11.0
3 cytochrome p450 oxidoreductase deficiency 11.0
4 prediabetes syndrome 10.9
5 hair-an syndrome 10.9
6 gestational diabetes 10.5
7 body mass index quantitative trait locus 1 10.4
8 endometrial adenocarcinoma 10.4
9 body mass index quantitative trait locus 11 10.4
10 body mass index quantitative trait locus 9 10.3
11 body mass index quantitative trait locus 8 10.3
12 body mass index quantitative trait locus 4 10.3
13 body mass index quantitative trait locus 10 10.3
14 body mass index quantitative trait locus 7 10.3
15 body mass index quantitative trait locus 12 10.3
16 body mass index quantitative trait locus 14 10.3
17 body mass index quantitative trait locus 18 10.3
18 body mass index quantitative trait locus 19 10.3
19 endometrial hyperplasia 10.3
20 rickets 10.3
21 alopecia 10.3
22 cystic teratoma 10.3
23 fatty liver disease 10.3
24 type 2 diabetes mellitus 10.3
25 placenta disease 10.3
26 sexual disorder 10.2
27 hypothyroidism 10.2
28 diabetes mellitus 10.2
29 ovarian hyperstimulation syndrome 10.2
30 cataract 10.2
31 schizophrenia 10.2
32 benign teratoma 10.2
33 duodenal ulcer 10.2
34 multiple endocrine neoplasia 10.2
35 teratoma 10.2
36 pseudohermaphroditism 10.2
37 pituitary adenoma 10.2
38 hypertrichosis 10.2
39 dysgerminoma 10.2
40 mature teratoma 10.2
41 bronchitis 10.2
42 muscular dystrophy 10.2
43 aminoaciduria 10.2
44 progressive muscular dystrophy 10.2
45 pre-eclampsia 10.1
46 endometriosis 10.1
47 acanthosis nigricans 10.1
48 lipoid congenital adrenal hyperplasia 10.1
49 androgenic alopecia 10.1
50 sleep apnea 10.1

Graphical network of the top 20 diseases related to Polycystic Ovary Syndrome 1:



Diseases related to Polycystic Ovary Syndrome 1

Symptoms & Phenotypes for Polycystic Ovary Syndrome 1

Human phenotypes related to Polycystic Ovary Syndrome 1:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 obesity 31 HP:0001513
2 enlarged polycystic ovaries 31 HP:0008675
3 abnormality of metabolism/homeostasis 31 HP:0001939
4 hirsutism 31 HP:0001007
5 amenorrhea 31 HP:0000141
6 oligomenorrhea 31 HP:0000876

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Growth:
obesity

Hair:
hirsutism

Misc:
response to bilateral wedge resection of the ovaries
increased frequency of early baldness or excessive hairiness in male first-degree relatives

G U:
enlarged polycystic ovaries
amenorrhea
oligomenorrhea

Endocrine:
no virilization

Lab:
normal 24-hr urinary ketosteroids
elevated dehydroepiandrosteronesulfate
increased 5-alpha-reductase activity in the liver and skin
elevated androstanedione and/or testosterone and luteinizing hormone
low estradiol and follicle-stimulating hormone levels
more

Clinical features from OMIM®:

184700 (Updated 05-Apr-2021)

UMLS symptoms related to Polycystic Ovary Syndrome 1:


pelvic pain

Drugs & Therapeutics for Polycystic Ovary Syndrome 1

Drugs for Polycystic Ovary Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
2
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
11
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
12
Simvastatin Approved Phase 4 79902-63-9 54454
13
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
14
Liraglutide Approved Phase 4 204656-20-2 44147092
15
Tamoxifen Approved Phase 4 10540-29-1 2733526
16
Alogliptin Approved Phase 4 850649-61-5 11450633
17
Sibutramine Approved, Illicit, Investigational, Withdrawn Phase 4 106650-56-0 5210
18
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
19
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
20
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
21
Citalopram Approved Phase 4 59729-33-8 2771
22
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
23
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
24
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
25
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
26
Drospirenone Approved Phase 4 67392-87-4 68873
27
Lactitol Approved, Investigational Phase 4 585-86-4 157355
28
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
29
Glucagon Approved Phase 4 16941-32-5
30
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
31
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
32
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
33
Topiramate Approved Phase 4 97240-79-4 5284627
34
Iron Approved Phase 4 7439-89-6 23925 29936
35
Canagliflozin Approved Phase 4 842133-18-0
36
Testosterone Approved, Investigational Phase 4 58-22-0 6013
37
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
38
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
39
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
40
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
41
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
44
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
45
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
47
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
48
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
49
Cobalamin Experimental Phase 4 13408-78-1 6857388
50
Dexetimide Withdrawn Phase 4 21888-98-2

Interventional clinical trials:

(show top 50) (show all 696)
# Name Status NCT ID Phase Drugs
1 Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
2 Adding L-carnitine in Clomiphene Resistant Pco Improves the Quality of Ovulation and the Pregnancy Outcome,a Randomized Clinical Trial Unknown status NCT01665547 Phase 4 l-carnitine
3 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
4 Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome. Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
5 Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome Unknown status NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
6 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
7 Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients Unknown status NCT03151005 Phase 4 Metformin-GLP-1 Receptor Agonist;Metformin-Oral Contraceptive(OC)
8 The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS). Unknown status NCT01588873 Phase 4 oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
9 Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
10 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
11 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
12 Endometrial Scratching at Time of Laproscopic Ovarian Drilling in Women With Anovulatory Infertility Due to Polycystic Ovarian Syndrome (PCOS): Randomized Controlled Trial. Unknown status NCT02140398 Phase 4
13 The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
14 Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
15 A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
16 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
17 The Effect Of Vitamin D Replacement Therapy On Serum Leptin And Follicular Growth Pattern In Women With Resistant Polycystic Ovarian Syndrome Unknown status NCT03806036 Phase 4 Vitamin D;Clomiphene Citrate
18 Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin Unknown status NCT03486626 Phase 4 Metformin
19 Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome Unknown status NCT02344888 Phase 4 Clomiphene citrate and Prednisolone;Clomiphene citrate and folic acid
20 Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients Unknown status NCT00883259 Phase 4 Metformin
21 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
22 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
23 Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study Unknown status NCT02215135 Phase 4 Corifollitropin alfa
24 N-acetyl Cysteine as an Adjuvant Therapy to Laparoscopic Ovarian Drilling in Clomiphene Citrate Resistant Polycystic Ovary Syndrome Completed NCT02239107 Phase 4 N-Acetyl cysteine
25 A Clinical Trial to Measure the Effect of DHA-enriched Fish Oils on Blood Pressure, Heart Rate Variability and Liver Fat Content in the Polycystic Ovary Syndrome Completed NCT00620529 Phase 4
26 Evaluate the Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4 clomiphene citrate with ethinyl esteradiol;clomiphene citrate with plasebo
27 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
28 Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation Completed NCT03352869 Phase 4 Exenatide;Metformin
29 Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4 HMG;rFSH
30 Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT01021579 Phase 4 Metformin plus Placebo;Metfomin plus Simvastatin
31 Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial Completed NCT01896492 Phase 4 NAC
32 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Completed NCT02483299 Phase 4 Metformin;Glucophage tablets and Victoza
33 Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role? Completed NCT03642600 Phase 4 dietary advice plus Liraglutide Pen Injector
34 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
35 Clomiphene Citrate Versus Tamoxifen for Induction of Ovulation in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial Completed NCT02479256 Phase 4 Clomiphene citrate;Tamoxifen Placebo;Tamoxifen;Clomiphene citrate placebo
36 Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome Completed NCT01899430 Phase 4 liraglutide;metformin
37 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
38 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
39 Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
40 Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
41 Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
42 Therapeutic Effect of Vitamin D3 Supplementation to Clomiphene Citrate Resistant Polycystic Ovary Syndrome Women Completed NCT04010942 Phase 4 Vit D;Metformin;Clomiphene
43 To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS) Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
44 Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
45 Does Short-term Structured Exercise Training Program Plus Diet Intervention Improve Ovarian Sensitivity to Clomiphene Citrate in Polycystic Ovary Syndrome Patients (PCOS)? A Prospective Randomized Controlled Study Completed NCT01004068 Phase 4 Clomiphene citrate
46 Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome Completed NCT02802865 Phase 4 Clomiphene;Letrozole
47 Metformin and Oral Contraceptives in PCOS Completed NCT00451568 Phase 4 Metformin;Desorelle
48 The Effect of Liraglutide on Pregnancy Rates in Obese Women With PCOS Undergoing in Vitro Fertilization: a Pilot Randomized Study Completed NCT03353948 Phase 4 MET;COMBI
49 Comparison of Oral Contraceptive Versus Physical Exercise Effects on Cardiovascular and Metabolic Risk Factors in PCOS Women Completed NCT00593294 Phase 4 OC - Drospirenone plus Ethynylestradiol
50 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Metabolic and Fertility Parameters in PCOS Women Completed NCT01721915 Phase 4 Vitamin D supplementation;Placebo

Search NIH Clinical Center for Polycystic Ovary Syndrome 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Urofollitropin

Genetic Tests for Polycystic Ovary Syndrome 1

Anatomical Context for Polycystic Ovary Syndrome 1

MalaCards organs/tissues related to Polycystic Ovary Syndrome 1:

40
Ovary, Endothelial, Liver, Bone, Pituitary, Skin, Cortex

Publications for Polycystic Ovary Syndrome 1

Articles related to Polycystic Ovary Syndrome 1:

(show top 50) (show all 607)
# Title Authors PMID Year
1
Hereditary factors in the Stein-Leventhal syndrome. 61 57
15782458 1968
2
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. 57
21151128 2011
3
Early metabolic derangements in daughters of women with polycystic ovary syndrome. 57
17848407 2007
4
Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. 57
17785364 2007
5
Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. 57
17426092 2007
6
Itchy-dry eye associated with polycystic ovary syndrome. 57
17362862 2007
7
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. 57
16849416 2006
8
Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. 57
16636126 2006
9
Heritability of polycystic ovary syndrome in a Dutch twin-family study. 57
16219714 2006
10
Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. 57
16091490 2005
11
A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. 57
15827106 2005
12
Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. 57
15507516 2005
13
Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. 57
15181035 2004
14
The prevalence and features of the polycystic ovary syndrome in an unselected population. 57
15181052 2004
15
Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. 57
15126571 2004
16
Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. 57
14602801 2003
17
Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. 57
12970273 2003
18
Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. 57
11932299 2002
19
Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. 57
11836280 2002
20
Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. 57
11344202 2001
21
Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. 57
11297583 2001
22
Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. 57
11238505 2001
23
Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. 57
11232039 2001
24
Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. 57
10852468 2000
25
A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. 57
10566641 1999
26
5alpha-reductase activity in women with polycystic ovary syndrome. 57
10404813 1999
27
A paradigm for finding genes for a complex human trait: polycystic ovary syndrome and follistatin. 57
10411866 1999
28
Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. 57
10411917 1999
29
Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. 57
9920059 1999
30
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. 57
9843997 1998
31
Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. 57
9745406 1998
32
The genetic basis of polycystic ovary syndrome. 57
9455828 1997
33
Leptin concentrations in the polycystic ovary syndrome. 57
9177364 1997
34
Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. 57
9147642 1997
35
Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. 57
7849715 1994
36
Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. 57
8334753 1993
37
5 alpha-reductase activity in polycystic ovary syndrome. 57
1968168 1990
38
Familial clustering in the polycystic ovarian syndrome. 57
2777131 1989
39
Familial polycystic ovarian disease. 57
3058473 1988
40
Pathogenesis and treatment of polycystic ovary syndrome. 57
3277057 1988
41
Late-onset adrenal hyperplasia in hirsutism. 57
2989686 1985
42
A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. 57
6633568 1983
43
HLA genotyping in family members and patients with familial polycystic ovarian disease. 57
6833465 1983
44
Late-onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease. 57
6977282 1982
45
Androgen production and skin metabolism in hirsutism. 57
925589 1977
46
Polycystic ovarian disease, maturation arrest of spermiogenesis, and Klinefelter's syndrome in siblings of a family with familial hirsutism. 57
803038 1975
47
Vitamin C suppresses ovarian pathophysiology in experimental polycystic ovarian syndrome. 61
31564389 2019
48
Compounding for Patients with Polycystic Ovarian Syndrome (Stein-Leventhal Syndrome). 61
31085787 2019
49
Kisspeptin and Polycystic Ovary Syndrome. 61
31156550 2019
50
Words do matter: a systematic review on how different terminology for the same condition influences management preferences. 61
28698318 2017

Variations for Polycystic Ovary Syndrome 1

Expression for Polycystic Ovary Syndrome 1

Search GEO for disease gene expression data for Polycystic Ovary Syndrome 1.

Pathways for Polycystic Ovary Syndrome 1

GO Terms for Polycystic Ovary Syndrome 1

Sources for Polycystic Ovary Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....